Breaking Down Guizhou Xinbang Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Investors scrutinizing Guizhou Xinbang Pharmaceutical Co., Ltd. will find a mixed financial portrait: in the first three quarters of 2025 the company reported operating revenue of CNY 4.266 billion (down 6.55% year‑over‑year) and a net profit attributable to shareholders of CNY 152 million (down 13.74% YoY), with trailing twelve‑month (TTM) revenue at CNY 5.73 billion and TTM net income of CNY 77.12 million (TTM EPS CNY 0.04 and a P/E of 87.30), against a 2024 full‑year revenue of CNY 6.03 billion (a 6.63% decline) and 2024 net income of CNY 101.38 million (a 64.70% drop); profitability metrics show a TTM net profit margin of approximately 1.35%, gross margin of 16.78% and ROE of 1.77% with five‑year average earnings contraction of 11% annually and net margin erosion from 3.5% to 1.3%, while balance‑sheet indicators point to improving leverage-debt‑to‑equity down from 72.7% to 7.2% over five years, total debt‑to‑equity at 11.47% (June 2024), net debt roughly CNY 89.9 million supported by cash reserves of CNY 730 million, operating cash flow covering 132.6% of debt, total assets of CNY 9.02 billion and total liabilities due within 12 months of CNY 1.88 billion; valuation and market signals include a market capitalization of CNY 6.32 billion, dividend of CNY 0.06 per share (yield 1.84%), a 52‑week range of CNY 3.14-4.85 and a 1.80% price uptick as of 19 Dec 2025, while material risks-such as a subsidiary bribery scandal, compressed margins, intensified competition and regulatory exposure-compete with growth levers like a focused cardiovascular/cerebrovascular portfolio (44 national approvals), ongoing R&D and expansion potential in domestic and international markets-read on for a detailed line‑by‑line breakdown and what these numbers mean for portfolio positioning

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) Revenue Analysis

Guizhou Xinbang Pharmaceutical's top-line has been contracting across the last two reporting periods, with profitability under pressure. Key reported figures highlight the trajectory from 2023 through the first three quarters of 2025 and the most recent trailing twelve months (TTM) snapshot.

• Operating revenue (1-3Q 2025): CNY 4.266 billion, down 6.55% year‑over‑year versus the same period in 2024.
• Net profit attributable to shareholders (1-3Q 2025): CNY 152 million, a 13.74% decline year‑over‑year.
• TTM revenue: CNY 5.73 billion; TTM net income: CNY 77.12 million.
• TTM EPS: CNY 0.04; trailing P/E: 87.30.

• The revenue decline from CNY 6.46bn (2023) to CNY 6.03bn (2024) represents a 6.63% contraction, and the 1-3Q 2025 run rate keeps the company below prior full‑year levels (TTM revenue CNY 5.73bn).
• Profitability deterioration is pronounced: 2024 net income fell ~64.70% vs 2023, and TTM net income of CNY 77.12m plus an EPS of CNY 0.04 produce a high P/E of 87.30, signaling market valuation premiums relative to near‑term earnings.
• Short‑term recovery signs are mixed: 1-3Q 2025 net profit of CNY 152m is higher than the 2024 full‑year net of CNY 101.38m, yet TTM net income remains depressed versus historical levels, indicating timing differences and potential volatility in quarterly results.

Further context on ownership, recent investor activity, and company disclosures can be found here: Exploring Guizhou Xinbang Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Profitability Metrics

Key profitability indicators for Guizhou Xinbang Pharmaceutical show constrained margins and declining earnings momentum over the last five years, with recent quarter figures slightly above the TTM average.

• TTM net profit margin: ~1.35%
• Latest quarter net profit margin: 1.68%
• Gross profit margin (TTM): 16.78%
• Return on equity (ROE): 1.77%
• Five‑year average earnings decline: -11% CAGR
• Net profit margin five‑year change: fell from 3.5% to 1.3%

• Revenue vs. profit dynamics: gross margin at 16.78% indicates positive markup on cost of goods sold, but operating costs, R&D, SG&A and financial expenses have compressed net margin to ~1.35% TTM.
• ROE implications: 1.77% ROE signals low efficiency converting equity into net income-investors should assess capital structure and asset utilization.
• Earnings trend: an average annual earnings decline of ~11% over five years, with net profit margin slipping from 3.5% to ~1.3%, highlights persistent margin pressure and/or one‑off losses.
• Quarterly variance: the latest quarter's net margin (1.68%) is modestly higher than the TTM average, suggesting possible short‑term improvement or seasonal effects.

For deeper context on strategy and corporate direction that may affect future profitability see: Mission Statement, Vision, & Core Values (2026) of Guizhou Xinbang Pharmaceutical Co., Ltd.

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Debt vs. Equity Structure

• Total debt-to-equity ratio (June 2024): 11.47%
• Net debt: ≈ CNY 89.9 million (cash reserves: CNY 730 million)
• Operating cash flow covers 132.6% of total debt
• Market capitalization: CNY 6.32 billion
• Current liabilities due within 12 months: CNY 1.88 billion
• Five-year debt-to-equity trend: 72.7% → 7.2% (significant deleveraging)

• Balance-sheet strength: positive net cash position when accounting for large cash buffers versus modest net debt.
• Liquidity consideration: CNY 1.88 billion in near-term liabilities requires ongoing cash generation despite strong operating cash coverage.
• Capital structure trend: material reduction in leverage over five years supports lower financial risk, though short-term ratio movements (11.47% vs. 7.2% low) warrant monitoring.

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Liquidity and Solvency

• Cash reserve: CNY 730,000,000 (on balance sheet)
• Net debt: ~CNY 89,900,000 (net of cash and interest-bearing debt)
• Total assets: CNY 9,020,000,000
• Operating cash flow vs. net income: operating cash flow significantly exceeds net income (most recent 12-month period)
• Current and quick ratios: not explicitly disclosed but inferred to be favorable given short-term asset coverage and cash position

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Valuation Analysis

• P/E Ratio (TTM): 87.30 - reflects a high valuation multiple versus trailing earnings.
• TTM EPS: CNY 0.04 - very modest trailing earnings per share driving the elevated P/E.
• Market Capitalization: CNY 6.32 billion - size context for liquidity and institutional interest.
• Dividend: CNY 0.06 per share; Dividend Yield: 1.84% - provides a modest cash return to shareholders.
• 52-Week Range: CNY 3.14 - CNY 4.85 - range of recent volatility and investor sentiment.
• Stock Price Movement: +1.80% as of 19 December 2025 - latest short-term performance snapshot.

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Risk Factors

• Subsidiary bribery scandal: One of the group's operating subsidiaries has been implicated in a bribery case involving procurement and marketing practices, raising immediate reputational and legal exposure.
• Declining profit margins: The company reported a trailing net profit margin of 1.3% in the most recent fiscal year, signaling severe margin compression vs. peers.
• Sustained earnings decline: Reported net income has fallen at an average annual rate of approximately 11% over the past five years.
• Low shareholder returns: Return on equity is weak at 1.77%, indicating limited profitability relative to equity base.
• Intense market competition: The firm competes in a crowded pharmaceutical market with generics, branded rivals and contract manufacturers pressuring prices and volumes.
• Regulatory risk: Potential changes in drug pricing, approvals, GMP enforcement and anti-corruption oversight could materially affect operations and margins.

Key numerical context (historical five-year snapshot):

• Operational consequences of the bribery case may include: investigations, fines, suspension/termination of contracts, heightened compliance costs, and loss of key distributors or hospital relationships.
• Margin pressure drivers: pricing concessions to maintain volume, rising R&D or raw material costs, and channel disputes can further compress the reported 1.3% margin.
• Cash-flow and capital allocation risks: Persistently low ROE (1.77%) and shrinking net income constrain internal cash generation for R&D, capex, or deleveraging.
• Investor considerations: monitor quarterly earnings for stabilization, management commentary on the subsidiary investigation, provisions or contingencies, and any regulatory sanctions.

For more on ownership, trading, and investor activity related to Guizhou Xinbang Pharmaceutical Co., Ltd., see: Exploring Guizhou Xinbang Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) - Growth Opportunities

Guizhou Xinbang Pharmaceutical targets niche therapeutic categories with a clear emphasis on cardiovascular and cerebrovascular drugs, positioning the company to capitalize on aging demographics and chronic disease prevalence in China and select overseas markets.

• Therapeutic focus: cardiovascular and cerebrovascular drugs - addressing large, persistent demand pools.
• Product breadth: 44 national drug approval numbers, providing a diversified commercial base and multiple revenue streams.
• Market cap: CNY 6.32 billion - mid-cap scale that implies potential for valuation appreciation as commercial execution and R&D translate into growth.
• Shareholder returns: consistent history of dividend payments, signaling management's attention to investor value.

Key expansion vectors:

• Domestic deepening - broaden hospital and retail channels for existing cardiovascular/cerebrovascular products, especially in second- and third-tier cities.
• Internationalization - target emerging markets with regulatory pathways favorable to Chinese generics and specialty products; licensing or distribution partnerships could accelerate entry.
• Pipeline evolution - ongoing R&D may convert into new formulations, indications, or biologics that raise average selling prices and margins.
• M&A and licensing - bolt-on acquisitions to complement the product portfolio or gain commercial footholds in priority geographies.

Investor considerations and catalysts to monitor:

• R&D milestones - clinical readouts or new approvals that materially expand marketable indications.
• Commercial metrics - widening hospital penetration, sales growth by product, and gross margin trends as higher-value products scale.
• Regulatory and reimbursement developments - national reimbursement inclusion or favorable provincial procurement outcomes could boost volumes.
• Capital allocation - continued dividends, share buybacks, or targeted M&A will signal management's growth vs. return priorities.

For the company's stated mission and strategic framing, see: Mission Statement, Vision, & Core Values (2026) of Guizhou Xinbang Pharmaceutical Co., Ltd.